{"id":"NCT03664674","sponsor":"Otonomy, Inc.","briefTitle":"Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease","officialTitle":"A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-27","primaryCompletion":"2020-12-22","completion":"2020-12-22","firstPosted":"2018-09-10","resultsPosted":"2022-12-07","lastUpdate":"2022-12-07"},"enrollment":148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Meniere Disease"],"interventions":[{"type":"DRUG","name":"OTO-104","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OTO-104","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.","primaryOutcome":{"measure":"28-Day Average DVD at Week 12 (Month 3)","timeFrame":"3 months","effectByArm":[{"arm":"OTO-104 Intent to Treat","deltaMin":2.869,"sd":null},{"arm":"Placebo Intent to Treat","deltaMin":3.577,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.312"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":65,"countries":["United States","Belgium","Germany","Italy","Poland","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37185596"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":73},"commonTop":["Meniere's disease","Vertigo","Tinnitus","Ear Pain","Ear Discomfort"]}}